CO.DON AG: Chairman of the Executive Board resigns from his position at the end of 2017
December 18, 2017 at 07:15 am EST
Share
DGAP-News: CO.DON AG / Key word(s): Change of Personnel
CO.DON AG: Chairman of the Executive Board resigns from his position at the end of 2017
18.12.2017 / 13:12
The issuer is solely responsible for the content of this announcement.
CO. DON AG - Chairman of the Executive Board resigns from his position at the end of 2017
Berlin / Teltow, 18.12.2017 - In agreement with the Supervisory Board, Mr. Dirk Hessel has resigned from his position as member and Chairman of the Management Board of CO. DON AG with effect from the end of December 31,2017 in order to take on new professional responsibilities. At the same time, the Supervisory Board agreed with Mr. Hessel to early termination of his contract, which would normally have ended at the end of June 14, 2018. During Mr. Hessel's time as CEO, CO. DON AG reached a significant milestone in its corporate development with the EU-wide approval of its Spherox product. On this basis, the company's Executive Board has defined the development of European markets as a new strategic goal and has begun the product launch in several European countries. The Supervisory Board of CO. DON AG would like to thank Mr. Hessel for the important contributions he has made in this decisive phase of the company's development and wishes him luck and success for his future professional tasks. The other member of the Executive Board, Mr. Ralf Jakobs, will continue to run the company as sole member of the Executive Board after Mr. Hessel's departure.
CO.DON AG develops, produces and markets autologous cell therapies for the minimally invasive repair of cartilage damage in knee joints following traumatic or degenerative defects. The product being marketed is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method has been used for more than 10 years in over 150 clinics to treat more than 11,000 patients. In Germany the statutory health insurance companies have paid for the treatment of knee and hip joints since 2007. In July 2017 the company received EU marketing authorization for Spherox. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Dirk Hessel (CEO), Ralf M. Jakobs (CFO).
More information can be found at www.codon.de
Investor Relations and Press Contact:
Matthias Meißner, M.A. Corporate communications / IR / PR Tel. +49 (0)30 240352330 Fax +49 (0)30 240352309 Email: ir@codon.de
18.12.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
CO.DON AG
Warthestraße 21
14513 Teltow
Germany
Phone:
03328 43460
Fax:
03328 434643
E-mail:
info@codon.de
Internet:
www.codon.de
ISIN:
DE000A1K0227
WKN:
A1K022
Listed:
Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
Co.don AG is a Germany-based company that is active in the tissue engineering and regenerative medicine industry. The Company manufactures cell-based biological drugs for the use in orthopedic and neurosurgical applications. Its products are used for the treatment of focal particular cartilage defects, lumbar disc herniation, non-union fractures and dental disorders. Those include co don chondrotransplant, which is used for cartilage treatment, particularly in the knee area; co don chondrosphere, which is a three-dimensional articular cartilage cultivated outside of the body; co don chondrotransplant DISC, for the regeneration of intervertebral discs, and co don osteotransplant DENT, which is an autologous bone cell transplant for dental applications. The Company is active domestically and in other European countries.
CO.DON AG 
